TITLE

EASL Roundup

PUB. DATE
April 2009
SOURCE
BioWorld Today;4/27/2009, Vol. 20 Issue 79, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the positive results from a Phase 1b single-agent study of oral antiviral drug, candidate, SCY-365, a cyclophilin inhibitor from Scynexis Inc. in adult patients with genotype 1 chronic hepatitis C virus (HCV). SCY-635 was said to be well tolerated with no serious adverse events, no discontinuations and no dose-limiting toxicities. Scynexis plans to initiate a Phase II study in patients infected with hepatitis C virus (HCV) in the second half of 2009.
ACCESSION #
38599604

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics